Generic Name and Formulations:
Erythromycin (as base) 333mg, 500mg; particles in tabs.
Arbor Pharmaceuticals, LLC
Indications for PCE:
Susceptible infections including upper and lower respiratory, skin and soft tissue, genitourinary, Legionnaires' disease, pertussis, listeriosis.
Preferably take 2hrs before meals. Usually 333mg every 8hrs or 500mg every 12hrs. Genitourinary: two 333mg tabs every 8hrs or 500mg 4 times daily for 7 days. Legionnaires: 1–4g daily in divided doses. Max 4g daily; twice daily dosing max 1g/day.
Preferably give 2hrs before meals. Mild-to-moderate infections: 30–50mg/kg/day; may double dose in severe infections. Both in divided doses. Max 4g daily.
Concomitant cisapride, pimozide, ergotamine, dihydroergotamine.
Hepatic dysfunction. Proarrhythmic conditions (eg, uncorrected hypokalemia or hypomagnesemia, clinically significant bradycardia); QT prolongation may occur, avoid. Myasthenia gravis. Elderly. Pregnancy (Cat.B). Nursing mothers.
See Contraindications. May potentiate or be potentiated by drugs metabolized by CYP3A (eg, carbamazepine, cyclosporine, tacrolimus, alfentanil, disopyramide, bromocriptine, rifabutin, quinidine, methylprednisolone, cilostazol, vinblastine). May potentiate or be potentiated by hexobarbital, phenytoin, valproate. May potentiate triazolam, midazolam, digoxin, theophylline, statins (rhabdomyolysis), sildenafil (reduce dose of sildenafil), colchicine (reduce starting dose of colchicine, max dose should be lowered; monitor). Hypotension, bradyarrhythmias, lactic acidosis with verapamil. Hypotension with calcium channel blockers metabolized by CYP3A4 (eg, verapamil, amlodipine, diltiazem). Increased anticoagulant effects with oral anticoagulants. QT prolongation with concomitant Class 1A (quinidine, procainamide) or Class III (dofetilide, amiodarone, sotalol) antiarrhythmics. May interfere with fluorometric detection of urinary catecholamines.
GI upset, abdominal pain, anorexia, hepatic dysfunction; QT prolongation.
Tabs 333mg—60; 500mg—100
Sign Up for Free e-newsletters
Psychiatry Advisor Articles
- Adjunctive Therapies for Bipolar Disorder Show Promise, Need More Evidence
- Predicting Treatment-Emergent Mania to Tailor Pharmacotherapy in Bipolar Disorder
- Abnormalities of Cortical Thickness in Bipolar Disorder With Auditory Hallucinations
- Antidepressants Increase Seizure Risk in Youth and Severely Depressed
- Prevalence of Major Depressive Disorder Remains High In US Population
- The Way to the Head May Be Through the Gut: Probiotics for Depression
- Suicide-Screening Toolkit Can Help Identify Youths at High Risk for Suicide
- Agoraphobia: An Evolving Understanding of Definitions and Treatment
- Parental Pressure to Diet Linked With Long-term Harm in Adolescents
- Does Access to Medical Cannabis Reduce Risk for Opioid Abuse?
- Suicide Risk After Self-Harm Among Adolescents, Young Adults
- E-Cigarettes Associated With More Harms Than Benefits at Population Level
- Safety, Efficacy of Deep Brain Stimulation for Alzheimer's
- Many Teens Who Use Tobacco Don't Self-Identify as Users
- Evidence of Methylphenidate Abuse: Characterizing Patterns of Use in Pediatric and Adult Populations